Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00240747
  4. Details
NCT00240747 Clinical Trial

Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients

Gram-Positive Bacterial Infections Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT00240747
Other study ID # RP59500V-324
Secondary ID
Status Terminated
Phase Phase 3
First received October 14, 2005
Last updated May 24, 2012
Start date June 2000
Est. completion date January 2005

Study information
Verified date May 2012
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Open-label, multicenter, multiple-dose, study of population pharmacokinetics of I.V. Synercid (7.5 mg/kg every 8 hours) in 75 pediatric patients. The purpose is to assess the population pharmacokinetics of Synercid in pediatric patients and to collect additional safety and efficacy data in pediatric patients.

Recruitment information / eligibility
Status Terminated
Enrollment 0
Est. completion date January 2005
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 27 Weeks to 16 Years
Eligibility Inclusion Criteria:

- Serious, suspected or documented gram-positive infection

Exclusion Criteria:

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Synercid

Locations
Country Name City State
United States Children's Hospital Cincinnati Ohio
United States The Cleveland Clinic Cleveland Ohio
United States Duke University Medical Center Durham North Carolina
United States Children's Hospital Oakland California
United States Children's Hospital of Orange County Orange California
United States Children's Hospital at Saint Francis Tulsa Oklahoma

Sponsors (2)
Lead Sponsor Collaborator
Pfizer Aventis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Population pharmacokinetics
Secondary Safety
Secondary Efficacy
See also
  Status Clinical Trial Phase
Completed NCT01412801 - Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings Phase 2
Terminated NCT00108433 - Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections Phase 3
Completed NCT00501150 - Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections N/A
Not yet recruiting NCT06444802 - Model-informed Precision Dosing for Linezolid Phase 3
Terminated NCT00529282 - A Study of Ceftobiprole in Patients With Fever and Neutropenia. Phase 3
Completed NCT00079976 - Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA) Phase 3
Terminated NCT00835783 - Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflammation N/A
Completed NCT00081744 - Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects Phase 3
Completed NCT03747497 - Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection Phase 2
Active, not recruiting NCT04911270 - Clinical Decision Support Tool for Vancomycin Dosing in Children N/A
Completed NCT02750761 - A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) Phase 1
Completed NCT00406198 - Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis Phase 4
Completed NCT03560440 - Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients
Completed NCT00147511 - Time To Efficacy and Onset Of Action Of Linezolid Phase 4
Not yet recruiting NCT04917380 - The Clinical Character，Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.
Completed NCT00736554 - What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Presenting to the Emergency Departments of a Canadian Academic Health Care Center? N/A
Completed NCT03361163 - Controlled Human Infection for Vaccination Against Streptococcus Pyogenes Phase 1
Completed NCT00167960 - Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit Phase 4
Completed NCT00874367 - Early-Onset Sepsis Surveillance Study N/A
Completed NCT00167999 - Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units Phase 4